Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797183 | 0.90 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL17909918 | 0.83 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL16797181 | 0.78 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL17909920 | 0.77 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL19471662 | 0.77 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL18268162 | 0.76 | RORC (0.75) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL17909917 | 0.76 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL16797179 | 0.76 | RORC (0.74) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL16797196 | 0.75 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL16797221 | 0.74 | RORC (0.71) | RORCCYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861612-B2 | Indolyl-containing RORγt inhibitors | ORCA PHARMACEUTICALS LIMITED (GB) | 2018-01-09 | — | — | US | claimed |
| US-20170050928-A1 | Compounds | ORCA PHARMACEUTICALS, LLC | 2017-02-23 | — | — | US | claimed |
| US-9861612-B2 | Indolyl-containing RORγt inhibitors | ORCA PHARMACEUTICALS LIMITED (GB) | 2018-01-09 | — | — | US | disclosed |
| US-9861612-B2 | Indolyl-containing RORγt inhibitors | ORCA PHARMACEUTICALS LIMITED (GB) | 2018-01-09 | — | — | US | disclosed |
| US-20170050928-A1 | Compounds | ORCA PHARMACEUTICALS, LLC | 2017-02-23 | — | — | US | disclosed |
| US-20170050928-A1 | Compounds | ORCA PHARMACEUTICALS, LLC | 2017-02-23 | — | — | US | disclosed |
| US-20170050928-A1 | Compounds | ORCA PHARMACEUTICALS, LLC | 2017-02-23 | — | — | US | disclosed |
| US-9522134-B2 | Compounds | ORCA PHARMACEUTICALS LIMITED (GB) | 2016-12-20 | — | — | US | disclosed |
| US-9522134-B2 | Compounds | ORCA PHARMACEUTICALS LIMITED (GB) | 2016-12-20 | — | — | US | disclosed |
| US-9522134-B2 | Compounds | ORCA PHARMACEUTICALS LIMITED (GB) | 2016-12-20 | — | — | US | disclosed |
| US-20160199348-A1 | Compounds | ORCA PHARMACEUTICALS LIMITED | 2016-07-14 | — | — | US | disclosed |
| US-20160199348-A1 | Compounds | ORCA PHARMACEUTICALS LIMITED | 2016-07-14 | — | — | US | disclosed |
| US-20160199348-A1 | Compounds | ORCA PHARMACEUTICALS LIMITED | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050928-A1 | Compounds | RORC, RORB, RORA | RORC 1/4885CYP2C9 184/4885CYP3A4 151/4885 |
| US-20160199348-A1 | Compounds | RORC, RORB, RORA | RORC 1/4885CYP2C9 398/4885CYP3A4 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.